Combining proteolysis targeting chimeras that target the same oncogenic cell surface proteins (EGFR, HER2 and MET) as respective antibodies, improved antibody internalization and enhanced the cytotoxicity of a HER2-targeting antibody drug conjugate.
- Ezequiel J. Tolosa
- Lin Yang
- Aaron S. Mansfield